Diatranz Otsuka Limited (DOL) develops cellular therapies through xenotransplantation to improve the lives of people with serious diseases, including type 1 diabetes, and provides testing and consultation services for xenotransplantation programs.
peer of
Metrics
marketPRIVATE
msh_idCOM:DOLGLOBAL
localenz
websitehttps://dolglobal.com/
source_ref7df278ca-d5b7-477f-87c5-157f8fe03845
products_or_servicesDIABECELL® for type 1 diabetes, testing and consultation services related to xenotransplantation.
New Zealand